Mubadala Capital is anchoring FWD Group’s Hong Kong IPO with a US$150 million investment, as the insurer looks to raise around US$500 million in a deal led by Morgan Stanley and Goldman Sachs.

A core product for Type 2 diabetes is expected to commercially launch in mainland China by the end of this year, subject to regulatory approval; CICC led the transaction.

Read on for the winners of the 29th iteration of the FinanceAsia Awards, across mainland China, Hong Kong SAR, Mongolia, South Korea and Taiwan.

The rationale behind all the winners for the best capital market deals across Asia Pacific.

Read on to find out the winners of our Deal Awards – Asia Pacific.

Li's practice at the international law firm will focus on fund formation and digital assets, across hedge funds, private equity, real estate and cryptocurrency.

The Chinese vehicle chip firm made its debut on the HKEX amid market instability, and saw a slump in its share price.

Read on to find out the winners of our Deal Awards – Asia.

Pundits have been calling Hong Kong's demise for decades, but with the rush of Chinese listings bringing in fresh liquidity, is it too soon to call time on the city as a financial hub?

Listing against the backdrop of social unrest in Hong Kong, China’s largest infant milk formula maker stays cautious with pricing and leaves something on the table for prospective investors.